The Relationship Between C-Reactive Protein and Atherosclerosis Differs on the Basis of Body Mass Index The Dallas Heart Study by Gupta, Nitin K. et al.
Journal of the American College of Cardiology Vol. 60, No. 13, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00Cardiac Risk
The Relationship Between C-Reactive
Protein and Atherosclerosis Differs
on the Basis of Body Mass Index
The Dallas Heart Study
Nitin K. Gupta, MD,* James A. de Lemos, MD,*†‡ Colby R. Ayers, MS,†§
Shuaib M. Abdullah, MD, MS,*†‡ Darren K. McGuire, MD, MHSC,*†‡§ Amit Khera, MD, MSC*†‡
Dallas, Texas
Objectives This study sought to evaluate whether the relationship between C-reactive protein (CRP) and atherosclerosis is
modified by body mass index (BMI).
Background CRP levels are affected by obesity, and it is unknown whether the associations between CRP and cardiovascular
(CV) disease differ between obese and nonobese individuals.
Methods We measured CRP and multiple atherosclerosis phenotypes, including coronary artery calcification (CAC) (n 
2,685), aortic wall thickness (AWT) (n  2,238), and aortic plaque burden (APB) (n  2,224), in subjects ages
30 to 65 years from the Dallas Heart Study. The associations of CRP with CAC, AWT, and APB were compared
across categories of BMI (normal, 18.5 to 25 kg/m2; overweight, 25 to 30 kg/m2; obese, 30 kg/m2) in
sex-stratified analyses.
Results The overall prevalence of obesity was 38% in men and 53% in women. Increasing CRP levels (1 mg/l, 1 to
3 mg/l, 3 mg/l) were associated with increased CAC prevalence in normal and overweight men and in normal
weight women (p  0.01), but not in obese subjects of either sex. Likewise, the correlations between CRP and
AWT and APB diminished with increasing BMI and were nonsignificant in obese individuals (p  0.05 in nono-
bese, p  0.1 in obese). Interaction tests between CRP and obesity were significant for all atherosclerosis mea-
sures in men and for AWT and ABP in women (p interaction 0.05 each). In both sexes, the c-statistics of CRP
for all 3 atherosclerosis measures were greater for normal weight than obese individuals.
Conclusions In a large, population-based study, the association between CRP and multiple measures of atherosclerosis is
diminished in obese individuals. The role of CRP for predicting CV outcomes in obese subjects requires further
evaluation. (J Am Coll Cardiol 2012;60:1148–55) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.050Numerous epidemiological studies have demonstrated an
association between elevated C-reactive protein (CRP)
levels and atherosclerotic cardiovascular (CV) disease (1–11).
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2012, accepted April 30, 2012.Despite persuasive epidemiological data, the majority of
studies relating CRP to CV disease have been composed of
patients who are less obese than the current U.S. popula-
tion, where now more than two-thirds of adults are over-
weight or obese (12). Because multiple epidemiological
studies have also demonstrated a robust association between
CRP and measures of obesity, it is plausible that the
differing metabolic profile seen in obese compared with
nonobese subjects may influence the relationship between
CRP and CV disease.
CRP is predominantly produced in the liver in response
to interleukin (IL)-6, which is one of several cytokines
released by activated leukocytes and smooth muscle cells in
atherosclerotic plaques (13–15). However, adipose tissue is
also a significant source of IL-6, which partially explains the
strong correlation between obesity and CRP (16,17). Thus,
the predictive value of CRP for CV disease may be
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from adipose tissue may predominate over the signal from
underlying atherosclerotic disease.
Given the uncertainty regarding the influence of obesity
on the association between CRP and CV disease, we sought
to determine whether the relationship between CRP and
atherosclerosis differs by body mass index (BMI) category in
a large, multiethnic, population-based cohort with a high
prevalence of obesity and multiple measures of well-
characterized atherosclerosis phenotypes.
Methods
Study population. The Dallas Heart Study (DHS) is a
multiethnic, population-based probability sample of Dallas
County adults. Details of the study design have been
described (18). The protocol was approved by the institu-
tional review board of the University of Texas Southwestern
Medical Center at Dallas, and all participants provided
written informed consent to participate in the study.
In brief, from an initial cohort of 6,101 subjects who
underwent a detailed in-home survey, 3,398 volunteered to
provide blood and urine samples for laboratory testing, and
2,971 subsequently underwent a clinic visit with various
imaging procedures, including coronary artery calcium
(CAC) assessment and magnetic resonance imaging for
aortic wall thickness (AWT) and aortic plaque burden
(APB) measurements. The present study excluded those
with BMI 18.5 (underweight) (n  9) and those with
incomplete data to calculate the Framingham Risk Score
(FRS) (n 63). Included in this cohort are those with CRP
and BMI values, as well as a valid measure of CAC (n 
2,685), AWT (n  2,238), or APB (n  2,224).
High-sensitivity CRP. Blood samples were obtained after
an overnight fast and stored for 4 h at 4°C in ethylene-
diaminetetraacetic tubes, and plasma aliquots were subse-
quently frozen at 80°C until biomarker assays were per-
formed. High-sensitivity CRP measurements were carried
out on thawed samples using the Roche/Hitachi 912 Sys-
tem, Tina-quant assay (Roche Diagnostics, Indianapolis,
Indiana), a latex-enhanced immunoturbidimetric method
(19). The minimal detectable range of this assay is 0.1 mg/l,
and the upper limit is 20 mg/l. Clinical validation of this
assay has been described (2).
Coronary artery calcification. An Imatron C-150XP
(Imatron Inc., San Francisco, California) electron-beam
computed tomography scanner was used to measure CAC,
with results expressed in Agatston units (20). Duplicate
scans were obtained 1 to 2 min apart, and the results were
averaged. A score of 10 Agatston units was selected as a
data-derived threshold to define the presence of CAC to
maximize signal-to-noise ratio and reproducibility (21).
Aortic wall thickness and aortic plaque burden. A 1.5-T
whole-body magnetic resonance imaging system (Intera,
Philips Medical Systems, Best, the Netherlands) was used
to obtain 6 transverse slices of the infrarenal abdominal haorta. Adventitial and luminal
borders were outlined to deter-
mine total vessel area and lumi-
nal area, respectively. The AWT
was calculated by subtracting the
luminal radius from the total ves-
sel radius, averaged over the 6
slices, as previously described
(22). Atherosclerotic plaque area
was identified by hyperintense
signal protrusions from the en-
doluminal surface (23). The
APB was calculated from the
ratio of plaque area to total vessel
area (24). The sex- and age-
specific (in 5-year increments)
75th percentile of AWT and
APB were calculated using data
from all subjects in the DHS
cohort with such measurements.
Study definitions. Hyperten-
sion was defined as one of the
following: systolic blood pressure
140 mm Hg, diastolic blood pressure90 mm Hg, or the
use of antihypertensive medication. Hypercholesterolemia
was defined as calculated low-density lipoprotein cholesterol
(LDL-C) 160 mg/dl (4.1 mmol/l) on a fasting sample,
irect LDL-C 160 mg/dl (4.1 mmol/l) on a nonfasting
ample, total cholesterol200 mg/dl (5.2 mmol/l), or use of
tatin medication. Low high-density lipoprotein cholesterol
HDL-C) was defined as HDL-C 40 mg/dl (1.04
mol/l) in men and 50 mg/dl (1.29 mmol/l) in women.
iabetes mellitus was defined by one of the following:
elf-report accompanied by use of antihyperglycemic med-
cation or by elevated serum glucose (fasting 126 mg/dl
7.0 mmol/l] or by nonfasting glucose 200 mg/dl [11.1
mol/l]). Family history of myocardial infarction was de-
ned as a first-degree male relative who had a myocardial
nfarction at age 50 years or a female relative at age 55
ears in survey responses. Race and ethnicity were defined
y subject self-report. Smoking was defined as cigarette use
ithin the previous 30 days and a lifetime history of having
moked100 cigarettes. BMI was calculated on the basis of
easured height and weight at study entry and categorized
s normal weight (18.5 to 25 kg/m2), overweight (25 to
30 kg/m2), and obese (30 kg/m2) (25). The FRS for
men and women was determined from major risk factors
(including age, smoking, total cholesterol, HDL-C, and
hypertension) according to the algorithm presented in the
National Cholesterol Education Program (NCEP)-Adult
Treatment Panel Three guidelines (26). Metabolic syn-
drome was defined as having 3 or more of 5 standard criteria
delineated by the NCEP (26). Subjects with self-reported
myocardial infarction or stroke were categorized in the
high-risk category (i.e., FRS20% 10-year risk of coronary
Abbreviations
and Acronyms
APB  aortic plaque
burden
AWT  aortic wall
thickness
BMI  body mass index
CAC  coronary artery
calcium
CRP  C-reactive protein
CV  cardiovascular
FRS  Framingham risk
score
HDL-C  high-density
lipoprotein cholesterol
IL  interleukin
LDL-C  low-density
lipoprotein cholesterol
NCEP  National
Cholesterol Education
Programeart disease) (26).
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CRP, Obesity, and Atherosclerosis September 25, 2012:1148–55Statistical analysis. Categoric data are reported as propor-
tions, and continuous data are reported as medians with
interquartile range (or mean values with standard deviations
if stated). Subjects were divided into BMI categories on the
basis of conventional definitions of normal weight (18.5 to
25 kg/m2), overweight (25 to 30 kg/m2), and obese
30 kg/m2) (25). All analyses were stratified by BMI
group. Given the previously published differing CRP dis-
tributions between men and women in the present cohort
Baseline Characteristics in WomenTable 1 Baseline Characteristics in Women
Overall 18.5 to <
N (%) 1,600 327 (
Age (yrs) 45 9.9 43
Race (%)
Black 830 (52%) 120 (
White 461 (29%) 150 (
Hispanic 285 (18%) 46 (
Hypertension (%) 568 (36%) 59 (
Hypercholesterolemia (%) 202 (13%) 24 (
Low HDL (%) 717 (45%) 81 (
Diabetes (%) 189 (12%) 9 (
Smokers (%) 384 (24%) 105 (
Metabolic syndrome (%) 618 (39%) 29 (
Family history of MI (%) 549 (34%) 91 (
BMI (kg/m2) 31 (26–36) 23 (
Waist circumference (inches) 38 (33–43) 31 (
FRS (% 10-yr risk) 1 (0–2) 0 (
CRP (mg/l) 3.9 (1.6–8.6) 1.4 (
Values are mean  SD or median (interquartile range).
BMI  body mass index; CRP  C-reactive protein; FRS  Framing
n/a  not applicable.
Baseline Characteristics in MenTable 2 Baseline Characteristics in Men
Overall 18.5 to
N (%) 1,299 316
Age (yrs) 44 9.5 44
Race (%)
Black 607 (47%) 165
White 444 (34%) 104
Hispanic 212 (16%) 34
Hypertension (%) 421 (32%) 67
Hypercholesterolemia (%) 183 (14%) 33
Low HDL (%) 451 (35%) 61
Diabetes (%) 144 (11%) 21
Smokers (%) 426 (33%) 137
Metabolic syndrome (%) 406 (31%) 28
Family history of MI (%) 387 (30%) 91
BMI (kg/m2) 28 (25–32) 23
Waist circumference (inches) 39 (36–43) 34
FRS (% 10-yr risk) 4 (1–10) 3
CRP (mg/l) 1.9 (0.9–4.2) 1.2
Values are mean  SD or median (interquartile range).
BMI  body mass index; CRP  C-reactive protein; FRS  Framingha
infarction; n/a  not applicable.(19), all analyses were sex stratified. Baseline demographic
variables and CV risk factors were compared across BMI
groups with chi-square trend test for categoric variables and
with the test for trend across ordered groups for continuous
variables. Subjects were categorized according to CRP
cutpoints based on clinically recommended values (1 mg/l,
1 to 3 mg/l, and 3 mg/l) (27), sex-specific tertiles within
the study cohort, and sex- and BMI-specific tertiles within
the study cohort. Associations between CRP category and
BMI
/m2 25 to <30 kg/m2 >30 kg/m2 p Value
427 (27%) 846 (53%) n/a
45 9.6 45 9.8 0.003
202 (47%) 508 (60%) 0.0001
130 (30%) 181 (21%) 0.0001
89 (21%) 150 (18%) 0.5
123 (29%) 386 (46%) 0.0001
48 (11%) 130 (15%) 0.0001
179 (42%) 457 (54%) 0.0001
21 (5%) 159 (19%) 0.0001
96 (23%) 183 (22%) 0.002
114 (26.7%) 475 (56.2%) 0.001
136 (32%) 322 (38%) 0.0004
) 28 (26–29) 36 (33–41) 0.0001
) 35 (33–37) 43 (43–46) 0.0001
0 (0–1) 1 (0–2) 0.0001
2.8 (1.4–5.3) 6.6 (3.2–12.4) 0.0001
k Score; HDL  high-density lipoprotein; MI  myocardial infarction;
BMI
g/m2 25 to <30 kg/m2 >30 kg/m2 p Value
491 (38%) 492 (38%) n/a
45 9.3 44 9.5 0.5
201 (41%) 241 (49%) 0.8
191 (39%) 149 (30%) 0.2
83 (17%) 95 (19%) 0.002
143 (29%) 211 (43%) 0.0001
80 (16%) 70 (14%) 0.3
164 (33%) 226 (46%) 0.0001
36 (7%) 87 (18%) 0.0001
159 (32%) 130 (26%) 0.0001
92 (19%) 286 (58%) 0.0001
144 (29%) 152 (31%) 0.5
4) 28 (26–29) 33 (32–36) 0.0001
5) 38 (37–40) 44 (42–47) .0001
4 (1–10) 4 (1–10) 0.08
.2) 1.6 (0.9–3.6) 2.6 (1.6–5.9) 0.000125 kg
20%)
 10
37%)
45%)
14%)
18%)
7%)
25%)
3%)
32%)
8.9%)
28%)
21–24
29–33
0–1)
0.6–3)<25 k
(24%)
 10
(52%)
(33%)
(11%)
(21%)
(11%)
(19%)
(7%)
(43%)
(9.9%)
(29%)
(22–2
(32–3
(1–8)
(0.5–3m Risk Score; HDL  high-density lipoprotein; MI  myocardial
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Odds ratios for prevalent CAC were calculated for CRP3
versus 3 mg/l and for FRS 20% versus 20% 10-year
risk. Interaction testing for obesity  CRP on prevalent
CAC was performed in sex-specific logistic models with
terms for obesity (BMI30 vs.30 kg/m2), categoric CRP
(3 vs. 3 mg/l), and their interaction. The correlations
between CRP and FRS with AWT and APB were assessed
using Spearman rank correlation coefficients. Interaction
tests for these continuous outcomes were assessed in sex-
specific linear regression models with similar obesity and
CRP interaction terms. The ability of CRP to discriminate
between those with and without CAC 10, AWT 75th
percentile, and APB 75th percentile was assessed by
calculating the c-statistic from logistic regression models.
All statistical analyses were performed using SAS Version
9.2 (SAS Institute Inc., Cary, North Carolina).
Results
The baseline characteristics of the study cohort stratified
by sex are summarized in Tables 1 and 2. The overall
prevalence of overweight and obesity was 27% and 53% in
women, respectively, and 38% and 38% in men, respec-
tively. In both men and women, most CV risk factors
were more prevalent in individuals with higher BMI.
Median CRP levels also increased across BMI categories in
both sexes, with larger increases among women as previ-
ously reported (28).
The prevalence of CAC according to CRP levels in
normal weight, overweight, and obese individuals stratified
by sex is shown in Figures 1 to 3. As CRP increased from
1 mg/l, to 1 to 3 mg/l, to3 mg/l, the prevalence of CAC
ncreased in normal weight women and in normal and
verweight men (p trend  0.01). However, in overweight
nd obese women, and in obese men, the prevalence of CAC
as not significantly different across CRP categories (Figs. 1A
nd 1B).
Sex-specific tertiles of CRP for this population were2.3
g/l, 2.3 to 6.6 mg/l, and 6.6 mg/l in women, and 1.3
g/l, 1.3 to 3.1 mg/l, and 3.1 mg/l in men. Using these
hresholds resulted in no change in the relationship between
RP and CAC, with significant associations only in normal
eight women and normal and overweight men (Figs. 2A
nd 2B). When sex- and BMI-specific tertiles of CRP were
valuated, higher CRP levels did track with an increased
revalence of CAC among obese women, but not among
bese men (Figs. 3A and 3B). However, the highest CRP
ertile in obese women involved a markedly high threshold
f CRP (9.9 mg/l). By using waist circumference catego-
ies instead of BMI, similar trends were seen with CRP
aving no statistical association with CAC among those
ith increased waist circumference (Table 3).
The odds ratio for CAC comparing CRP3 mg/l versus
3 mg/l was also only significant in normal weight womennd normal and overweight men, but not in the obese groupor either sex (Table 4) (p interaction obesity  CRP  not
ignificant in women, 0.04 in men). In contrast, a high FRS
20% 10-year risk) was strongly associated with prevalent
AC in all BMI categories of both sexes.
The correlations between CRP and AWT and APB
iminished with increasing BMI category, with no signifi-
ant correlations among obese participants, whereas FRS
emained correlated with these aortic atherosclerosis mea-
ures across all BMI groups (p  0.001) (Table 5). Inter-
ction tests for obesity  CRP were significant for both
women and men for AWT (p interaction 0.01 and 0.002,
respectively) and APB (p interaction  0.005 and 0.04,
respectively).
In stratified analyses including the presence or absence of
metabolic syndrome and BMI categories, CRP correlated
with both AWT and ABP in normal weight women with or
without the metabolic syndrome but was not associated with
0
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Figure 1 CAC Prevalence by CRP Clinical
Categories and BMI in Women and Men
(A) Increasing CRP clinical categories are associated with CAC in normal
weight women, but not in overweight or obese women. (B) Increasing CRP clini-
cal categories are associated with CAC in normal weight and overweight men,
but not in obese men. BMI  body mass index; CAC  coronary artery calci-
um; CRP  C-reactive protein, in mg/l.either measure among obese women regardless of metabolic
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metabolic syndrome, CRP correlated with both AWT and
ABP in normal and overweight subjects, but not in the
obese. However, there was no statistical correlation between
CRP and these aortic parameters in any BMI category
among men with metabolic syndrome, although there were
few normal weight men with this condition (n  28).
The ability of CRP to discriminate between the presence
or absence of CAC, AWT, and ABP, as measured by
c-statistics, is shown for each BMI category in Table 6. In
both women and men, normal weight individuals tended to
have higher c-statistics than obese individuals for all 3
atherosclerosis measures.
Discussion
In this large, multiethnic, population-based cohort, obe-
sity modified the associations between CRP and multiple
0
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Figure 2 CAC Prevalence by Sex-Specific
CRP Tertiles and BMI in Women and Men
(A) Increasing sex-specific CRP tertiles are associated with CAC in normal
weight women, but not in overweight or obese women. (B) Increasing sex-spe-
cific CRP tertiles are associated with CAC in normal weight and overweight
men, but not in obese men. Abbreviations as in Figure 1.measures of atherosclerosis, such that the associations ofCRP with atherosclerosis observed in normal weight
individuals were diminished and nonsignificant among
obese subjects. In contrast, the associations between the
FRS and the atherosclerosis measures were significant
across all BMI categories. These findings raise important
0
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Figure 3 CAC Prevalence by Sex- and BMI-Specific
CRP Tertiles and BMI in Women and Men
(A) Increasing sex- and BMI-specific CRP tertiles are associated with CAC in
normal weight and obese women. The threshold for the upper sex- and BMI-
specific CRP tertile in obese women is 9.9 mg/l. (B) Increasing sex- and
BMI-specific CRP tertiles are associated with CAC in normal weight and over-
weight men, but not in obese men. Abbreviations as in Figure 1.
Prevalence of Coronary Artery Calcium by CRPCutpoints Among W ist Circumference CategoriesTable 3 Prevalence of Coronary Artery Calc um by CRPCutpoints Among Waist Circumference Categories
CRP, mg/l
Waist Circumference
Men <1 1 to 3 >3 p Value for Trend
40 inches 33 (14%) 62 (22%) 70 (36%) 0.0001
40 inches 24 (32%) 72 (32%) 79 (40%) 0.10
Women
35 inches 10 (6%) 15 (9%) 21 (14%) 0.01
35 inches 13 (20%) 40 (17%) 129 (19%) 0.80CRP  C-reactive protein in mg/l.
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individuals.
Despite the rapid increase in the prevalence of obesity,
few data are available regarding the utility of current CV
risk prediction tools in obese subjects. Previous studies
linking CRP levels to CV outcomes were largely performed
in populations with a lower prevalence of obesity than that
of the current U.S. population (1–11), where more than
one-third of adults are now obese (12). For example, in the
2 largest published studies of CRP and CV disease (2,11),
he mean BMI of participants ranged from 25 to 26 kg/m2,
ower than the recent reported mean of 28.7 kg/m2 in U.S.
adults (29). In contrast, the Strong Heart Study examined
the relationship between CRP and CV disease in a popu-
lation with a high prevalence of obesity (mean BMI 30
kg/m2) (30). After multivariable adjustment for demo-
graphic variables and traditional risk factors, no significant
association was observed between elevated CRP levels (3
mg/l) and CV events. However, subgroup analyses examin-
ing these relationships in obese compared with nonobese
subjects were not performed (30). Likewise, in the REGARDS
(Reasons for Geographic and Racial Differences in Stroke)
Odds Ratio for Coronary Artery Calcium With High CRP or FraminghTable 4 Odds Ratio for Coronary Artery Calcium With High CRP
BMI 18.5 to <25 kg/m2
OR (95% CI) p Value OR
Women
CRP 3 2.5 (1.2–5.0) 0.013 1.3
FRS 20 8.2 (2.7–25.0) 0.0002 4.6
Men
CRP 3 2.1 (1.2–3.7) 0.008 2.5
FRS 20 3.0 (1.3–7.0) 0.01 6.8
BMI  body mass index; CI  confidence interval; CRP  C-reactive protein in mg/l; FRS  F
Correlation Coefficients for CRP andFramingham Risk Score With Aortic WallThickness and Aortic Plaque Burden by BMI Category
Table 5
rrelatio Co fficients for CRP and
Framingham Risk Score With Aortic Wall
Thickness and Aortic Plaque Burden by BMI Category
BMI
18.5 to <25 kg/m2
BMI
25 to <30 kg/m2
BMI
>30 kg/m2
Rho p Value Rho p Value Rho p Value
Aortic wall thickness
Women
CRP 0.20 0.001 0.13 0.02 0.04 0.30
FRS 0.42 0.0001 0.34 0.0001 0.37 0.0001
Men
CRP 0.31 0.0001 0.10 0.04 0.04 0.50
FRS 0.59 0.0001 0.47 0.0001 0.48 0.0001
Aortic plaque burden
Women
CRP 0.24 0.0001 0.11 0.04 0.001 0.90
FRS 0.45 0.0001 0.40 0.0001 0.36 0.0001
Men
CRP 0.34 0.0001 0.16 0.001 0.08 0.10
FRS 0.50 0.0001 0.48 0.0001 0.45 0.0001Rho  correlation coefficient; other abbreviations as in Table 4.cohort of 27,000 individuals, CRP levels 3 mg/l were
ost informative for all-cause mortality in underweight and
ormal-weight individuals, rather than the severely obese (p
nteraction  0.01, white subjects) (31).
The predictive accuracy of CRP in obese subjects may be
ffected by the close correlation between CRP and adipos-
ty. IL-6 is the principle cytokine that stimulates CRP
elease from the liver, and up to one-third of circulating
L-6 is released from adipose tissue (16,17). Furthermore,
RP is more closely correlated with measures of body
omposition than with any traditional CV risk factors (19).
or example, approximately 15% of the variance in CRP is
etermined by BMI compared with less than 3% due to
DL cholesterol (32,33). Therefore, the increase in CRP
evels seen with obesity may lead to an overestimation of CV
isk among obese subjects. In fact, it has been hypothesized
hat despite heightened inflammation in severely obese
ndividuals, they may actually be protected from vascular
ysfunction and atherosclerosis. One study demonstrated
eightened mobilization of endothelial progenitor cells in
orbidly obese versus obese subjects (34), whereas another
tudy reported reduced expansion of CD4CD28nullT cells,
directly cytotoxic lymphocytes that possess proatheroscle-
rotic properties, in the morbidly obese (35). In addition, the
increased risk factor burden seen in obese individuals may
offer competing risk and blunt the CV risk signal of CRP in
these individuals, particularly because CRP only modestly
correlates with these risk factors (32,33).
C-Statistic of CRP for Coronary Arteryalcium, Aortic Wall Thick ess, andAor ic Plaque Burden by BMI Category
Table 6
C-Statistic f CRP for Coronary Artery
Calcium, Aortic Wall Thickness, and
Aortic Plaque Burden by BMI Category
BMI
18.5 to 25 kg/m2
BMI
25 to <30 kg/m2
BMI
>30 kg/m2
Women
CAC 10 0.643 0.563 0.569
AWT 75thpercentile 0.553 0.520 0.509
APB 75thpercentile 0.606 0.545 0.539
Men
CAC 10 0.619 0.617 0.541
AWT 75thpercentile 0.552 0.516 0.510
APB 75thpercentile 0.631 0.528 0.595
isk Score by BMI Categoryramingham Risk Score by BMI Category
I 25 to <30 kg/m2 BMI > 30 kg/m2
CI) p Value OR (95% CI) p Value
.2) 0.40 1.3 (0.8–2.1) 0.20
6.9) 0.02 5.2 (2.9–9.6) 0.0001
.0) 0.0001 1.3 (0.9–2.0) 0.20
3.9) 0.0001 12.4 (4.7–33.1) 0.001
ham Risk Score in percent 10-year risk; OR  odds ratio.am Ror F
BM
(95%
(0.7–2
(1.3–1
(1.6–4
(3.3–1APB  aortic plaque burden; AWT  aortic wall thickness; CAC  coronary artery calcium;
other abbreviations as in Table 1.
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CRP, Obesity, and Atherosclerosis September 25, 2012:1148–55Among overweight individuals in this study, the associ-
ation between CRP and CAC differed between women and
men, with positive associations only in overweight men.
One possible explanation for this finding is that CRP levels
increase to a greater degree with increased adiposity in
women compared with men (19,28). Alternatively, over-
weight women may have a greater quantity of body fat
compared with overweight men, despite being in the same
BMI category (36).
BMI is a crude measure of total body adiposity, and
central adiposity as measured by waist circumference may be
a superior marker of metabolic risk. By using NCEP-
defined waist circumference cutpoints rather than BMI
categories, we observed similar results with increasing CAC
prevalence with higher CRP levels among those with
normal waist circumference, but not among those with
increased waist circumference. In addition, in the Women’s
Health Study, CRP was only informative for CV events
among those with the metabolic syndrome, and not all
obese individuals meet criteria for this entity (37). Never-
theless, we did not observe any association between CRP
and atherosclerosis among obese subjects with or without
the metabolic syndrome.
Consistent with our previous report (38), CRP is gener-
ally a poor predictor of subclinical atherosclerosis with an
overall c-statistic of 0.56 for the discrimination of detectable
CAC. However, we observed a trend toward decreasing
c-statistic values for obese compared with normal weight
subjects, such that the statistically significant associations
between CRP and multiple atherosclerosis measures found
in normal weight subjects were not evident in obese sub-
jects. It is plausible that higher CRP thresholds may be
required in obese populations to reveal associations with CV
disease. For example, the Strong Heart Study investigators
demonstrated that using an upper CRP threshold of 4 mg/l,
as opposed to 3 mg/l, resulted in higher CV risk estimates,
which remained significant after multivariable adjustment
(30). Current Centers for Disease Control and Prevention/
American Heart Association recommendations of using a
threshold of 3 mg/l to denote high relative risk are based on
the tertiles of CRP distribution from selected cohorts with
a lower prevalence of obesity than that in the U.S. popula-
tion and the DHS (27). Adjusting CRP cutpoints based on
sex-specific tertiles within the study cohort did not
strengthen the association between CRP levels and CAC in
obese individuals, but using sex- and BMI-specific cutpoints
did result in a statistically significant association between
CRP and CAC in obese women. However, the cutpoint
required to detect this relationship involved a markedly high
threshold of CRP (9.9 mg/l) that requires exploration and
confirmation in other cohorts and with clinical events.
Despite the large sample size, ethnic diversity, and high
prevalence of obesity of this population-based cohort, sev-
eral potential limitations merit comment. First, the reduced
accuracy of CRP as a marker of prevalent atherosclerosis in
obese subjects could represent imprecision of these athero-sclerosis measurements in obese individuals and lead to
misclassification bias. However, using a threshold of 10
Agatston units for detectable CAC has been shown to have
90% interscan concordance in those with BMI 30
kg/m2 (21). In addition, when using FRS as a control, we
bserved little change in the strong relationship between
RS and CAC, AWT, and APB with increasing BMI.
lso, the interaction testing for CRP and obesity on
revalent CAC was not significant among women. How-
ver, the interaction tests were significant in women for
oth AWT and ABP and across all atherosclerosis pheno-
ypes in men, and the low prevalence of CAC in women
educed the power to detect a significant interaction in this
roup. Finally, our findings regarding the effects of obesity
n the relationship between CRP and radiographic mea-
ures of atherosclerosis cannot be directly extrapolated to
linical CV events. CRP may be more reflective of
upture-prone, unstable coronary plaques than the bur-
en of atherosclerotic disease (39). Further studies with
linical endpoints are needed to explore the utility of CRP
esting in obese subjects, including an assessment of optimal
isk cutpoints.
onclusions
n a large, multiethnic, population-based study, obesity
odifies the association between CRP and atherosclerosis,
uch that the association between CRP and multiple ath-
rosclerosis phenotypes is diminished in obese individuals of
oth sexes. Because CRP may be a better marker of plaque
nstability than plaque presence, additional studies with
linical events are needed to clarify the relationship between
RP and CV outcomes in obese individuals.
Reprint requests and correspondence: Dr. Amit Khera, Division
of Cardiology, UT Southwestern Medical Center, 5909 Harry
Hines Boulevard, Room HA9.133, Dallas, Texas 75390-9047.
E-mail: amit.khera@utsouthwestern.edu.
REFERENCES
1. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective
study of C-reactive protein, homocysteine, and plasma lipid levels as
predictors of sudden cardiac death. Circulation 2002;105:2595–9.
2. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and
other circulating markers of inflammation in the prediction of coronary
heart disease. N Engl J Med 2004;350:1387–97.
3. Koenig W, Sund M, Frohlich M, et al. C-Reactive protein, a sensitive
marker of inflammation, predicts future risk of coronary heart disease
in initially healthy middle-aged men: results from the MONICA
(Monitoring Trends and Determinants in Cardiovascular Disease)
Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237–42.
4. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive
protein and coronary heart disease in the MRFIT nested case-control
study. Multiple Risk Factor Intervention Trial. Am J Epidemiol
1996;144:537–47.
5. Festa A, D’Agostino R, Jr., Williams K, et al. The relation of body fat
mass and distribution to markers of chronic inflammation. Int J Obes
Relat Metab Disord 2001;25:1407–15.
6. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomark-
ers, hormone replacement therapy, and incident coronary heart disease:
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
1155JACC Vol. 60, No. 13, 2012 Gupta et al.
September 25, 2012:1148–55 CRP, Obesity, and Atherosclerosisprospective analysis from the Women’s Health Initiative observational
study. JAMA 2002;288:980–7.
7. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospec-
tive study of C-reactive protein and the risk of future cardiovascular
events among apparently healthy women. Circulation 1998;98:731–3.
8. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH.
Inflammation, aspirin, and the risk of cardiovascular disease in appar-
ently healthy men. N Engl J Med 1997;336:973–9.
9. Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive
protein and risk of ischemic stroke and transient ischemic attack: the
Framingham study. Stroke 2001;32:2575–9.
0. Mora S, Rifai N, Buring JE, Ridker PM. Additive value of
immunoassay-measured fibrinogen and high-sensitivity C-reactive
protein levels for predicting incident cardiovascular events. Circulation
2006;114:381–7.
1. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of
C-reactive protein and low-density lipoprotein cholesterol levels in the
prediction of first cardiovascular events. N Engl J Med 2002;347:
1557–65.
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends
in obesity among US adults, 1999-2008. JAMA 2010;303:235–41.
3. Khera A. C-reactive protein. In: De Lemos JA, editor. Biomarkers in
Heart Disease. Malden: Blackwell Publishing, 2008:161–180.
4. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868–74.
5. Pepys MB, Hirschfield GM. C-reactive protein: a critical update.
J Clin Invest 2003;111:1805–12.
6. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose
tissue releases interleukin-6, but not tumor necrosis factor-alpha, in
vivo. J Clin Endocrinol Metab 1997;82:4196–200.
7. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflamma-
tion, obesity, stress and coronary heart disease: is interleukin-6 the
link? Atherosclerosis 2000;148:209–14.
8. Victor RG, Haley RW, Willett DL, et al. The Dallas Heart Study: a
population-based probability sample for the multidisciplinary study of
ethnic differences in cardiovascular health. Am J Cardiol 2004;93:
1473–80.
9. Khera A, McGuire DK, Murphy SA, et al. Race and gender
differences in C-reactive protein levels. J Am Coll Cardiol 2005;46:
464–9.
0. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M,
Jr., Detrano R. Quantification of coronary artery calcium using
ultrafast computed tomography. J Am Coll Cardiol 1990;15:827–32.
1. Jain T, Peshock R, McGuire DK, et al. African Americans and
Caucasians have a similar prevalence of coronary calcium in the Dallas
Heart Study. J Am Coll Cardiol 2004;44:1011–7.
2. Rosero EB, Peshock RM, Khera A, Clagett GP, Lo H, Timaran C.
Agreement between methods of measurement of mean aortic wall
thickness by MRI. J Magn Reson Imaging 2009;29:576–82.
3. Jaffer FA, O’Donnell CJ, Larson MG, et al. Age and sex distribution
of subclinical aortic atherosclerosis: a magnetic resonance imaging
examination of the Framingham Heart Study. Arterioscler Thromb
Vasc Biol 2002;22:849–54.
4. Rohatgi A, Owens AW, Khera A, et al. Differential associations
between soluble cellular adhesion molecules and atherosclerosis in the
Dallas Heart Study: a distinct role for soluble endothelial cell-selective
adhesion molecule. Arterioscler Thromb Vasc Biol 2009;29:1684–90.5. Executive summary of the clinical guidelines on the identification,
evaluation, and treatment of overweight and obesity in adults. Arch
Intern Med 1998;158:1855–67.
6. Executive Summary of The Third Report of The National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation,
And Treatment of High Blood Cholesterol In Adults (Adult Treat-
ment Panel III). JAMA 2001;285:2486–97.
7. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflam-
mation and cardiovascular disease: application to clinical and public
health practice: a statement for healthcare professionals from the
Centers for Disease Control and Prevention and the American Heart
Association. Circulation 2003;107:499–511.
8. Khera A, Vega GL, Das SR, et al. Sex differences in the relationship
between C-reactive protein and body fat. J Clin Endocrinol Metab
2009;94:3251–8.
9. Walls HL, Stevenson CE, Mannan HR, et al. Comparing trends in
BMI and waist circumference. Obesity (Silver Spring) 2011;19:216–9.
0. Best LG, Zhang Y, Lee ET, et al. C-reactive protein as a predictor of
cardiovascular risk in a population with a high prevalence of diabetes:
the Strong Heart Study. Circulation 2005;112:1289–95.
1. Lakoski SG, Le AH, Muntner P, et al. Adiposity, inflammation, and
risk for death in black and white men and women in the united states:
the Reasons for Geographic and Racial Differences in Stroke (RE-
GARDS) Study. J Clin Endocrinol Metab 2011;96:1805–14.
2. Kathiresan S, Larson MG, Vasan RS, et al. Contribution of clinical
correlates and 13 C-reactive protein gene polymorphisms to interin-
dividual variability in serum C-reactive protein level. Circulation
2006;113:1415–23.
3. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels
and outcomes after statin therapy. N Engl J Med 2005;352:20–8.
4. Biasucci LM, Graziani F, Rizzello V, et al. Paradoxical preservation of
vascular function in severe obesity. Am J Med 2010;123:727–34.
5. Graziani F, Cialdella P, Liuzzo G, et al. Cardiovascular risk in obesity:
different activation of inflammation and immune system between
obese and morbidly obese subjects. Eur J Intern Med 2011;22:418–23.
6. Gallagher D, Visser M, Sepulveda D, Pierson RN, Harris T, Heyms-
field SB. How useful is body mass index for comparison of body fatness
across age, sex, and ethnic groups? Am J Epidemiol 1996;143:228–39.
7. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the
metabolic syndrome, and risk of incident cardiovascular events: an
8-year follow-up of 14 719 initially healthy American women. Circu-
lation 2003;107:391–7.
8. Khera A, de Lemos JA, Peshock RM, et al. Relationship between
C-reactive protein and subclinical atherosclerosis: the Dallas Heart
Study. Circulation 2006;113:38–43.
9. Burke AP, Tracy RP, Kolodgie F, et al. Elevated C-reactive protein
values and atherosclerosis in sudden coronary death: association with
different pathologies. Circulation 2002;105:2019–23.
Key Words: atherosclerosis y inflammation y obesity.
APPENDIX
For a supplementary table on the study protocol,
please see the online version of this article.
